Welcome to our dedicated page for Moringa Acquisition news (Ticker: MACA), a resource for investors and traders seeking the latest updates and insights on Moringa Acquisition stock.
Moringa Acquisition Corp (Nasdaq: MACA), a special purpose acquisition company targeting innovative technology firms, is currently advancing its merger with clinical-stage biotech leader Silexion Ltd. This comprehensive news hub provides investors with essential updates on the proposed business combination and related developments in RNA-based cancer therapeutics.
Access verified information about merger milestones, regulatory filings, and clinical trial progress for Silexion's oncology pipeline. Our curated collection features official press releases, SEC disclosures, and strategic updates regarding the planned Nasdaq listing of the combined entity.
Key focus areas include merger approval timelines, development of SIL-204B therapeutic candidates, and financial implications of the $62.5 million valuation. Bookmark this page for real-time updates on shareholder voting processes and post-merger leadership appointments.
For stakeholders monitoring this transformative biotech transaction, we maintain strict adherence to factual reporting from primary sources. Return regularly for critical updates as Moringa progresses toward completing this strategic combination in 2024.
Silexion Therapeutics (NASDAQ: SLXN) is emerging as a disruptive player in precision oncology, developing RNAi therapies for KRAS-driven cancers. Their proprietary LODER™ platform has shown promising results in Phase 2 trials for locally advanced pancreatic cancer, demonstrating a 9.3-month improvement in overall survival when combined with standard chemotherapy.
Silexion's second-generation product, SIL-204, targets a broader range of KRAS mutations and is set to enter Phase 2/3 trials in 2025-2026. The company's innovative approach addresses key challenges in pancreatic cancer treatment, including late detection, aggressive tumor growth, and drug resistance.
With the global precision medicine market projected to reach $470.53 billion by 2034, Silexion's focus on KRAS-driven cancers positions it as a potential acquisition target in a landscape of increasing M&A activity in the oncology space.
Moringa Acquisition Corp (NASDAQ: MACA) announced the adjournment of its Extraordinary Meeting, initially scheduled for February 7, 2023, to February 9, 2023. This meeting aims to vote on extending the deadline for completing a business combination from February 19, 2023, to August 19, 2023. Shareholders are advised to participate and review the Definitive Proxy Statement filed with the SEC. The company previously entered into a business combination agreement with Holisto Ltd., a tech-powered travel agency. The record date for shareholders to vote remains January 3, 2023.
On June 13, 2022, Holisto Ltd and Moringa Acquisition Corp (Nasdaq: MACA) announced a merger agreement, enabling Holisto to become publicly listed. The combination values Holisto at approximately $405 million and provides non-redeeming Moringa shareholders with a bonus of up to 1,725,000 shares. Holisto, leveraging AI technology, aims to disrupt the $194 billion online hotel booking market with personalized offerings. The transaction is expected to close in Q4 2022, subject to shareholder and Nasdaq approvals.
Moringa Acquisition Corp (NasdaqCM: MACA, MACAU, MACAW) filed its annual report on Form 10-K for the year ended December 31, 2021, with the SEC on March 31, 2022. This report is accessible through their official website and the SEC's site. The company targets mergers and acquisitions, particularly focusing on technology firms related to Israel. The press release also includes a reminder that forward-looking statements are based on management's beliefs and assumptions, and actual results may differ due to various factors.
Moringa Acquisition Corp has announced the pricing of its initial public offering (IPO) at $10.00 per unit, totaling 10,000,000 units. The units will be listed on Nasdaq under the symbol 'MACAU' starting February 17, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, allowing the purchase of additional shares at $11.50. The Company aims to focus on Israel-related technology firms and has engaged EarlyBirdCapital, Inc. and Moelis & Company as joint book-running managers. A registration statement was approved by the SEC on February 16, 2021.
